Predicting GLP-1 Discontinuation From Pharmacy Claims
Published: | Updated:
|Articles|August 1, 2004
Supplements and Featured Publications
- Newsletter - Inflammation, Metabolic Syndrome, and CV Risk Reduction
- Volume 10
- Issue 2 Metab
CE / CME
Advertisement
Articles in this issue
about 22 years ago
Commentaryabout 22 years ago
Post Testabout 22 years ago
Faculty Disclosure Statementabout 22 years ago
Metabolic syndrome: A new target of therapy?Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
Student Mental Health, Success Tied to Future Health and Affordability
3
FDA Approves First Orexin Agonist for Narcolepsy Type 1
4
Mobile Integrated Health Valuable in Heart Failure, but Payment Lags
5